Special Report: The deal with telehealth platform Practice Innovators International will give Respiri more exposure to a fast-growing sector.

Software as a Service (SaaS) health tech company Respiri (ASX:RSH) has scored a key distribution deal for the Asia-Pac region, ahead of the marquee launch of its Wheezo product later this year.

The Wheezo is a patented device which gives asthma patients a round-the-clock solution to monitor their symptoms, along with other external factors such as air conditions.

The deal will see Respiri partner with the Australian division of Practice Innovators International (PII) – provider of the proprietary telehealth platform GPNow.

The two companies are expected to sign a Joint Development Agreement which will be followed by field trials in the September quarter, ahead of the launch of an “integrated AsthmaCare Telehealth Service offering” in Q4, Respiri said.

Among PII various telehealth solutions, the company has recently launched CoronavirusCare – a secure service that facilities video appointments with medical professionals to assess symptoms, which can then be bulk-billed under Medicare.

Importantly, PII has also developed business-to-business (B2B) distribution channels with partners across Singapore, Malaysia, Indonesia and the Philippines.

As a result, Respiri’s integration with the platform will give an opportunity to explore “commercial opportunities in Southeast Asia”, the company said.

READ MORE: Respiri scores another key deal after joining forces with national telehealth platform Phenix; shares jump +50pc

Upon integration, the two companies will develop training in the use of Wheezo for PII’s B2B partners, as part of the broader telehealth service offering.

PII CEO Robert Hicken said the ability to leverage analytics insights from the Wheezo platform, as part of a telehealth consultation with a GPNow-certified doctor, creates “powerful combination to help asthmatics both locally and internationally”.

“Marrying Respiri’s world-class technology with our private and contact-free telehealth service represents a powerful,  safe and secure vehicle with enormous reach for delivery of comprehensive AsthmaCare plans,” Hicken said.

This story was developed in collaboration with Respiri, a Stockhead advertiser at the time of publishing.
This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.